skip to Main Content
Antios Therapeutics Announces Agreement With IRBM, INGM And OSR To Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), and IRBM, a drug discovery and early development research institute and global contract research organization, announced today they entered into an agreement for Antios to purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) being developed for the treatment of HBV.
IRBM To Collaborate With MSD To Develop Peptides Against Coronavirus

IRBM to collaborate with MSD to develop peptides against coronavirus

Builds on Research to Combat Severe Acute Respiratory Syndrome (SARS)
Rome, Italy – IRBM, a global Contract Research Organization today announced a new research collaboration agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA) to identify and develop novel peptide therapeutics active against different strains of coronavirus, including SARS-CoV-2.
In Memory Of Maurizio Botta: His Vision Of Medicinal Chemistry

In Memory of Maurizio Botta: His Vision of Medicinal Chemistry

IRBM’s medicinal chemists are incredibly proud to have contributed 3 articles to a special issue of the ACS Medicinal Chemistry Letters in memory of Professor Maurizio Botta. Many of our chemistry team were former students of the professor and are therefore thrilled to be part of this tribute.
Back To Top